培美曲塞用药期间会发生哪些眼部毒性? |
本文旨在提供关于使用培美曲塞期间眼部毒性概要的相关信息,仅供医疗卫生专业人士参考。 |
回复:
- 在临床试验和上市后监测中报告的培美曲塞的眼部毒性包括结膜炎、干眼和流泪增加/眼睛多泪/流泪。1-4
- 结膜炎是培美曲塞联合顺铂作为非小细胞肺癌和间皮瘤诱导治疗临床试验中报告的常见不良反应。3
- 多项已发表的临床试验均报告了在接受培美曲塞单药或与其他药物联用作为非小细胞肺癌诱导治疗的患者均出现了流泪增加、眼睛多泪、流泪或泪溢症的不良反应。5-9
参考文献
1Augustoni F, Platania M, Vitali M, et al. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev. 2014;40(1):197-203. http://dx.doi.org/10.1016/j.ctrv.2013.05.005
2Mennecier B, Bigay-Game L, Corre R, et al. Maintenance par pemetrexed dans les cancers bronchopulmonaires: comment optimiser la prise en charge à long terme? The Oncologist Letter. 2014;XXIII(8):344-349. https://www.edimark.fr/Front/frontpost/getfiles/21866.pdf
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
4Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881-895. https://doi.org/10.1016/j.annonc.2021.04.008
5Rusthoven JJ, Eisenhauer E, Butts C, et al; National Cancer Institute of Canada Clinical Trials Group. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non–small-cell lung cancer: a phase II study. J Clin Oncol. 1999;17(4):1194-1199. http://dx.doi.org/10.1200/jco.1999.17.4.1194
6Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. 2001;92(3):595-600. http://dx.doi.org/10.1002/1097-0142(20010801)92:3%3C595::AID-CNCR1359%3E3.0.CO;2-D
7Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005;104(11):2449-2456. http://dx.doi.org/10.1002/cncr.21480
8Chow LQM, Blais N, Jonker DJ, et al. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;69(3):709-722. http://dx.doi.org/10.1007/s00280-011-1755-0
9Ellis PM, Chu QS, Leighl N, et al. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non–small-cell lung cancer. Clin Lung Cancer. 2013;14(1):19-27. http://dx.doi.org/10.1016/j.cllc.2012.04.003
10Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer. J Clin Oncol. 2013;31(23):2895-2902. http://dx.doi.org/10.1200/JCO.2012.47.1102
11Pujol JL, Paz-Ares L, de Marinis F, et al. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer. Clin Lung Cancer. 2014;15(6):418-425. http://dx.doi.org/10.1016/j.cllc.2014.06.007